| Zacks Company Profile for BioMarin Pharmaceutical Inc. (BMRN : NSDQ) |
|
|
| |
| • Company Description |
| BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.?The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.
Number of Employees: 3,040 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $58.82 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 2,020,817 shares |
| Shares Outstanding: 191.78 (millions) |
| Market Capitalization: $11,280.24 (millions) |
| Beta: 0.17 |
| 52 Week High: $94.85 |
| 52 Week Low: $52.93 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
2.69% |
-1.16% |
| 12 Week |
-0.59% |
-16.38% |
| Year To Date |
-10.51% |
-16.19% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
770 Lindaro Street
-
San Rafael,CA 94901
USA |
ph: 415-506-6700
fax: 415-382-7889 |
ir@bmrn.com |
http://www.bmrn.com |
|
|
| |
| • General Corporate Information |
Officers
Alexander Hardy - President and Chief Executive Officer
Richard A. Meier - Chairman
Brian R. Mueller - Executive Vice President and Chief Financial Offic
Erin Burkhart - Group Vice President
Elizabeth McKee Anderson - Director
|
|
Peer Information
BioMarin Pharmaceutical Inc. (CORR.)
BioMarin Pharmaceutical Inc. (RSPI)
BioMarin Pharmaceutical Inc. (CGXP)
BioMarin Pharmaceutical Inc. (BGEN)
BioMarin Pharmaceutical Inc. (GTBP)
BioMarin Pharmaceutical Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09061G101
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/04/25
|
|
Share - Related Items
Shares Outstanding: 191.78
Most Recent Split Date: (:1)
Beta: 0.17
Market Capitalization: $11,280.24 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.84 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $3.48 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 11.00 |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: 20.98% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/04/25 |
|
|
|
| |
